D.A. Davidson & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

D.A. Davidson & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,118	Closed	-$223K	–	1386
2022 Q1	$223K	Buy	+2,118	New	+$206K	﹤0.01%	1170
2019 Q2	–	Sell	-12,615	Closed	-$333K	–	1196
2019 Q1	$333K	Buy	12,615 +2,023	+19%	+$47.9K	0.01%	832
2018 Q4	$207K	Buy	10,592 +512	+5%	+$10K	﹤0.01%	979
2018 Q3	$197K	Sell	10,080 -5	-0%	-$95	﹤0.01%	1081
2018 Q2	$167K	Hold	10,085	–	–	﹤0.01%	1045
2018 Q1	$143K	Buy	+10,085	New	+$149K	﹤0.01%	1031
2017 Q3	–	Sell	-300	Closed	-$3K	–	2250
2017 Q2	$3K	Hold	300	–	–	﹤0.01%	2280
2017 Q1	$4K	Sell	300 -2,850	-90%	-$46.2K	﹤0.01%	2220
2016 Q4	$50K	Hold	3,150	–	–	﹤0.01%	1598
2016 Q3	$56K	Sell	3,150 -1,139	-27%	-$22.3K	﹤0.01%	1478
2016 Q2	$69K	Sell	4,289 -4,374	-50%	-$70.8K	﹤0.01%	1276
2016 Q1	$142K	Sell	8,663 -17,157	-66%	-$300K	﹤0.01%	974
2015 Q4	$559K	Sell	25,820 -6,476	-20%	-$126K	0.02%	510
2015 Q3	$640K	Buy	32,296 +3,741	+13%	+$118K	0.02%	475
2015 Q2	$991K	Buy	28,555 +280	+1%	+$8.54K	0.03%	413
2015 Q1	$734K	Sell	28,275 -18,425	-39%	-$338K	0.02%	476
2014 Q4	$601K	Buy	46,700 +1,055	+2%	+$13.2K	0.02%	529
2014 Q3	$560K	Buy	+45,645	New	+$530K	0.02%	557

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

D.A. Davidson & Co's HZNP Position: Q2 2022 in Review

D.A. Davidson & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 2,118 shares — an estimated $223K sold.

D.A. Davidson & Co first reported a position in HZNP in Q3 2014 and held it in 18 quarters. The position peaked at $991K in Q2 2015. 614 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

D.A. Davidson & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
D.A. Davidson & Co sold 2,118 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $223K.
D.A. Davidson & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and held it in 18 quarters.
D.A. Davidson & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $991K in Q2 2015.
614 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on D.A. Davidson & Co's 13F filing for Q2 2022, filed 28 Jul 2022.